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1  | INTRODUC TION
Pulmonary surfactant is a lipoprotein complex that lines the alveo‐
lar spaces and is synthesized, stored and secreted by alveolar type 
II (ATII) cells. Surfactant is crucial for normal breathing, its main 
function is to lower the surface tension at the air‐liquid interface 
to prevent end‐expiratory collapse of alveolar units.1‐4 The storage 
compartments for surfactant are the lysosome‐derived lamellar bod‐
ies (LBs). Adenosine triphosphate (ATP)‐binding cassette subfam‐
ily A member 3 (ABCA3), a lipid transporter involved in surfactant 
homoeostasis, is localized at the outer membrane of lamellar bod‐
ies.5‐8 Like all ABC transporters it is composed of two transmem‐
brane domains (TMDs) that form a pore and two nucleotide‐binding 
domains (NBDs) that bind and hydrolyse ATP to generate the energy 
to transport surfactant lipids into the lumen of LBs.9,10
Phosphatidylcholine (PC) is the most abundant lipid species in 
human pulmonary surfactant11 and was shown to be transported 
by ABCA3.6 We recently established a functional assay to quantify 
the lipid transport function of ABCA3 by assessing the fluorescence 
intensity of TopFluor‐labeled PC (TopF‐PC) inside ABCA3‐positive 
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Abstract
ABCA3 is a phospholipid transporter implicated in pulmonary surfactant homoeosta‐
sis and localized at the limiting membrane of lamellar bodies, the storage compart‐
ment for surfactant in alveolar type II cells. Mutations in ABCA3 display a common 
genetic cause for diseases caused by surfactant deficiency like respiratory distress 
in neonates and interstitial lung disease in children and adults, for which currently no 
causal therapy exists. In this study, we investigated the effects of ivacaftor and gen‐
istein, two potentiators of the cystic fibrosis transmembrane conductance regulator 
(CFTR), on ABCA3‐specific lipid transport function. Wild‐type (WT) and functional 
ABCA3 mutations N568D, F629L, G667R, T1114M and L1580P were stably ex‐
pressed in A549 cells. Three‐dimensional modelling predicted functional impairment 
for all five mutants that was confirmed by in vitro experiments (all <14% of WT func‐
tional activity). Treatment with potentiators rescued the mutants N568D (up to 114% 
of WT), F629L (up to 47% of WT), and G667R (up to 60% of WT), the latter variation 
needing higher concentrations of genistein, showing reduced affinity of the potentia‐
tor to the mutant protein. Our results present a first proof that functional ABCA3 
mutations are rescued by CFTR potentiators, making them a potential therapeutical 
option for patients suffering from surfactant deficiency due to ABCA3 mutations.
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vesicles that resemble LBs in A549 cells.12 The overall transport ac‐
tivity, expressed as the fluorescence intensity per vesicle in all mea‐
sured vesicles is thereby composed of three different parameters: 
the volume of the vesicles, the portion of filled vesicles and the fluo‐
rescence intensity in filled vesicles.
Mutations in ABCA3 lead to surfactant deficiency and pulmo‐
nary diseases like fatal respiratory distress in newborns or chronic 
interstitial lung disease in children (chILD) and adults.13,14 To date, no 
causal therapies exist to treat patients suffering from lung diseases 
due to ABCA3 mutations. It is therefore a major task to identify 
pharmacological modulators for ABCA3 that would allow to treat 
those diseases.
In cystic fibrosis, a pulmonary disease caused by mutations in 
the ABC transporter cystic fibrosis transmembrane conductance 
regulator (CFTR, ABCC7),15,16 compounds have successfully been 
developed, which partially or completely correct the molecular de‐
fect in a mutation‐specific manner. Misfolding mutations, like the 
most frequent variation F508del, that lead to impaired processing 
and trafficking through the cell due to ER retention can be targeted 
by so called correctors that increase the delivery of CFTR to the 
cell surface.17‐20 Functional mutations, like the third‐most frequent 
CFTR variation G551D, that display impaired function but correct 
processing and localization, can be rescued by potentiators.17,20‐22 
CFTR potentiators ivacaftor (IVA) and genistein (GEN) lead to an in‐
crease in CFTR transport activity at the cell surface by enhancing its 
open probability (P0).
For ABCA3 we showed that a treatment with correctors rescued 
processing, trafficking, localization and function of misfolding muta‐
tions.23 Since a lot of ABCA3 mutations are classified as functional 
mutations, the main goal of this study was to evaluate the effect 
of potentiators on the lipid transport function of those mutations. 
Therefore we analysed three well‐described functional ABCA3 mu‐
tants, namely N568D in NBD1, T1114M in TMD2 and L1580P in 
NBD2.24‐26 We additionally analysed F629L and G667R variations, 
which were homologous to positions F508 and G550 in CFTR re‐
spectively (Figure 1A and B). G667R is located in the NBD1 con‐
served ABC signature motif, similarly affected in G551D in CFTR. It 
was selected because a rare variant has been described in humans 
in this position.27
All five mutants showed severely impaired lipid transport func‐
tion that was rescued by treatment with the CFTR potentiators 
ivacaftor (IVA) and genistein (GEN) in mutants N568D, F629L and 
G667R. The results presented here might pave the way for muta‐
tion‐group specific treatment of pulmonary diseases caused by 
ABCA3 mutations.
2  | MATERIAL S AND METHODS
2.1 | Molecular modelling
Structural models of wild‐type and mutant ABCA3 were build using 
phyre2 protein modelling webserver.28 The model of ABCA3 full‐
length in its unbound conformation was build based on the 4.1Å 
electron microscopy structure of human ABCA1 (pdbid: 5XJY).29 
Solely the NBD1‐2 and the TMD1‐2 were kept in the final model. 
These regions have an identity of 46% with the template, ensur‐
ing an accurate prediction of ABCA3 structure. The model of the 
NBD1‐NBD2‐ATP was modelled based on the 3.25Å crystallography 
structure of bacterial MacB dimer bound to ATP (pdbid: 5LJ7).30 The 
NBD1 and NBD2 of ABCA3 have identities of 30% and 22% respec‐
tively to the template NBD domain of MacB. Mutations in the TMD 
(T1114M) or of the TMD/NBD interface (F629L) were modelled on 
full‐length ABCA3 while mutations close to the ATP binding sites 
(N568D, G667R and L1580P) were modelled on the NBD1‐NBD2‐
ATP assembly.
2.2 | Sequence analysis
Protein sequence alignment between ABCA3 and CFTR was per‐
formed with the UniProt sequence alignment online tool.31 F629 
and G668 were identified to correspond to F508 and G551 in CFTR 
(Figure 1B). Variations F629L and G667R were identified using the 
Exome Aggregation Consortium (ExAc) Browser,27 with G667 corre‐
sponding to G550 in CFTR since no mutation was listed for position 
G668 in ABCA3.
Conservation analysis was performed with ConSurf Server.32 
Initial sequence selection was performed on the Uniref90 database 
using an E‐value threshold of 0.0001. Within this pool, the best 137 
ABCA3 sequences were manually selected. Final alignment was per‐
formed with the MAFFT‐L‐INS‐i method and scoring was calculated 
using the Bayesian method.
2.3 | Potentiators
Ivacaftor (VX‐770, IVA) was purchased from Sellekchem (Munich, 
Germany). Genistein (GEN) was purchased from Sigma Aldrich 
(Taufkirchen, Germany). Both substances were dissolved in dimethyl 
sulphoxide (DMSO, Sigma).
2.4 | Cell culture
A549 cells were obtained from the German Collection of 
Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany) 
and cultured in RPMI 1640 medium (Life technologies, Darmstadt, 
Germany) supplemented with 10% foetal bovine serum (FBS, Sigma) 
at 37°C and 5% CO2.
2.5 | Plasmids
A pT2/HB transposon vector (Addgene, Cambridge, plasmid#26557) 
was generated, containing hABCA3 cDNA (NM_001089) with cor‐
responding CMV promoter elements fused to a C‐terminal HA‐
tag and puromycin resistance gene, as described before.33 Single 
point mutations p.N568D (c.1702 A > G), p.F629L (c.1887 C > G), 
p.G667R (c.1999 G > A), p.T1114M (c.3341 C > T), and p.L1580P 
(c.4739 T > C) were introduced into the vector using the Q5® 
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F I G U R E  1   Localization and molecular consequences of five functional ABCA3 mutations. A, Two‐dimensional (2D) topology model 
of ABCA3 with marked positions of the five analysed functional mutations. Scissors mark cleavage site for processing of the 190 to 
170 kDa form. EL: external loop, A: Walker A motif, B: Walker B motif, C: C motif. B, Sequence alignment between ABCA3 and cystic 
fibrosis transmembrane conductance regulator (CFTR) to identify amino acids homologous to F508 and G551 in CFTR. Variations F629L 
and G667R were identified using the Exome Aggregation Consortium (ExAc) Browser,27 with G667 corresponding to G550 in CFTR since no 
mutation was listed for position G668 in ABCA3. A solid line indicates the conserved ABC signature motif (LSGGQ). C, Full‐length 3D model 
of ABCA3 with detailed pictures of location and consequences of the five functional ABCA3 mutations (i) N568D, (ii) F629L, (iii) G667R, 
(iv) T1114M, (v) L1580P. Mutated residues are represented as grey spheres in the full‐length model. In the detailed pictures, the side chains 
of the wild‐type residues are represented in full sticks and the substituting residues are shown in transparent grey sticks at each mutated 
position. Other residues of interest and ATP are also represented in stick when required; likely hydrogen bonds of interest are represented 
as blue dotted lines. ATP: adenosine triphosphate; NBD: nucleotide‐binding site; TMD: transmembrane domain
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site‐directed mutagenesis kit (NEB, Massachusetts, United States). 
Primer sequences are given in the Supporting Information Materials 
and Methods Section.
2.6 | Transfection and generation of stable 
cell clones
Transfection of A549 cells using the sleeping beauty transposon 
system34 and generation of stable cell clones were performed as de‐
scribed before.33
2.7 | Protein isolation and Western blotting
A549 cells were lysed in radioimmunoprecipitation assay (RIPA) 
buffer [0.15 mol/L sodium chloride, 1% Triton‐X 100, 0.5% so‐
dium deoxycholate, 0.1% sodium dodecylsulfate, 5 mmol/L ethyl‐
ene diamine tetraacetic acid (EDTA), 50 mmol/L Tris (pH 8)] (Sigma, 
EDTA from GE Healthcare, Buckinghamshire, UK, Tris from Merck 
Millipore, Darmstadt, Germany), supplemented with complete pro‐
tease inhibitor (Roche, Mannheim, Germany). Protein concentrations 
were measured using the Pierce BCA protein assay (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA) and 15 µg protein was sep‐
arated on NuPage Mini 3‐8% Tris‐Acetate gels (Invitrogen, Waltham, 
Massachusetts, USA) and subsequently transferred to a polyvi‐
nylidene fluoride (PVDF) membrane (Merck Millipore). For probing 
of ABCA3‐HA, rat anti‐HA monoclonal antibody (Roche) and rab‐
bit anti‐rat IgG (H + L) HRP secondary antibody (Southern Biotechs, 
Birmingham, AL) were used. β‐Actin (Santa Cruz, Dallas, TX) probing 
served as a loading control. SuperSignal® West Femto Maximum 
Sensitivity Substrate (Thermo Fisher Scientific) was used for detec‐
tion. Densitometric analysis was performed with Image J software.
2.8 | Immunofluorescence staining and 
confocal microscopy
For immunofluorescent stainings, cells were seeded in ibiTreat slides 
(ibidi, Martinsried, Germany). Cells were fixed with 4% paraformal‐
dehyde (Merck Millipore) and permeabilized with 0.5% TritonX‐100 
(Sigma). Cells were incubated with blocking solution [3% bovine 
serum albumin (BSA, Sigma) and 10% FBS in PBS] to block unspe‐
cific binding sites. ABCA3‐HA protein and CD63 were probed with 
anti‐HA (Sigma) and anti‐CD63 antibody (abcam, Cambridge, UK), 
and according AlexaFluor secondary antibodies (life technologies). 
Nuclei	were	stained	by	 incubation	with	0.1	µg/ml	4′,6‐diamidin‐2‐
phenylindol (DAPI, life technologies). Subsequently, cells were 
covered in mounting medium [90% glycerin in PBS and 2% 1,4‐di‐
azabicyclo[2.2.2]octane (DABCO, Sigma)] and images were acquired 
using a ZEISS LSM 800 with ZEN 2 blue edition software.
2.9 | TopFluor‐PC transport quantification
Surfactant‐like liposomes were prepared and transport of TopFluor‐
labeled phosphatidylcholine (TopF‐PC) into HA‐positive vesicles 
was quantified as described before.12 In short, TopF‐PC contain‐
ing liposomes (1:20 diluted in OptiMEM, Thermo Fisher Scientific) 
were offered to the cells expressing WT or mutant ABCA3‐HA for 
30 minutes at 4°C. After two hours at 37°C, cells were treated with 
potentiators or DMSO as a vehicle control for 24 hours. Then cells 
were covered with 5% BSA (in PBS) for 30 minutes at 4°C for re‐
moval of residual labelled lipids adherent to the cell membrane. Cells 
were fixed, permeabilized with saponin (Carl Roth GmBH, Karlsruhe, 
Germany) and stained for HA‐tag. Microscopy, fluorescence analysis 
and quantification of vesicle volume and percentage of filled vesicles 
were performed as described previously12 using a confocal laser‐
scanning microscope (LSM 800, ZEISS with ZEN 2 blue edition soft‐
ware) and the modified Fiji (Image J) plugin “Particle_in_Cell‐3D”.35
2.10 | Statistical analysis
Data are shown as means ± SEM. Statistical significance among 
means was calculated using one‐way ANOVA with Dunnet's post 
hoc test to compare to the WT or DMSO vehicle‐treated control. 
P < 0.05 was considered significant.
3  | RESULTS
3.1 | ABCA3 mutations are predicted to be 
functional mutations according to an ABCA3 3D 
model
Three‐dimensional structure modelling was performed and molecu‐
lar consequences of all five mutations were consistently predicted 
to impair function of the ABCA3 lipid transport activity (Figure 1). 
These observations are indicated for each mutation below.
The residue N568 is located in the conserved Walker A motif. Its 
side chain is directly involved in the binding of the third phosphate 
group of ATP. The loss of the side chain amine induced by the N568D 
mutation likely prevents this interaction and reduces or completely 
prevents ATP binding to ABCA3 (Figure 1C,i).
Residue F629, homologous to F508 in CFTR (Figure 1B), is very 
well conserved and is located in the NBD1 at a hydrophobic pocket, 
making interface with the transverse helices of TMD1. Substitution 
of a phenylalanine by a leucine prevents some hydrophobic interac‐
tions and may hinder the allosteric transmission of conformational 
changes to the TMD following ATP hydrolysis (Figure 1C,ii).
G667R is located in the conserved ABC signature motif (LSGGQ) 
(Figure 1B) implicated in ATP binding at the NDB1/NBD2 interface. 
In the ATP‐bound form G667 is in close proximity to phosphate 
groups 2 and 3 of the ATP molecule. A substitution to an arginine 
adds a large side chain that cannot be accommodated and prevents 
ATP binding (Figure 1C,iii).
Residue T1114 is located in the second helix of the TMD2, far 
from the NBDs (Figure 1C,iv). It likely forms a hydrogen bond with 
the conserved residue Q929 in the loop following the first trans‐
verse helix of the TMD2. Its mutation to a methionine precludes this 
hydrogen bonding and might prevent conformational changes of the 
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TMD2 happening upon ATP hydrolysis in the NBDs and thereby re‐
duce the transport activity of the protein.
Residue L1580 is located in a highly conserved helix following 
the H‐loop. Its mutation to a proline, incompatible with helical sec‐
ondary structure, has likely a strong impact on the conformation of 
this region and of the close H‐loop that interacts with ATP and the 
NBD1 (Figure 1C,v).
In summary, based on these data from 3D modelling, we ex‐
pected functional impairment of all five mutants, making them 
possible targets for treatment with potentiators to rescue the func‐
tional defect.
3.2 | Functional ABCA3 mutants display correct 
subcellular localization and processing but impaired 
lipid transport function in A549 cells
WT ABCA3‐HA and all five mutant proteins were stably expressed 
in A549 cells and showed vesicular structures that resemble LBs 
and co‐localized with the lysosomal marker CD63, demonstrating 
their correct protein localization (Figure 2A). However, the vesicles 
formed by all mutant proteins were significantly smaller than those 
in WT‐ABCA3 expressing cells (Figure 2B).
N‐terminal cleavage of ABCA3 in post‐Golgi compartments 
resulting in the presence of two products of about 190 and 
170 kDa,36,37 serves as a marker for correct protein traffick‐
ing.23,37,38 All five mutant proteins showed both processing products 
in Western blots (Figure 2C) with a ratio of 170 to 190 kDa form not 
significantly different from the WT protein, indicating correct pro‐
cessing and trafficking through the cell (Figure 2D).
Despite normal processing and localization, all five mutants ex‐
hibited a strong decrease in lipid transport activity compared to WT 
as predicted from the 3D model (Figure 3A and E, no treatment). 
Volume of the analysed vesicles, the portion of filled vesicles and the 
fluorescence intensity in filled vesicles were diminished for all mu‐
tants compared to WT, resulting in a transport activity of 14% of WT 
in N568D and T1114M mutants, 12% activity of WT in F629L and 
G667R mutants and 10% of WT lipid transport activity in L1580P 
mutant (Figure 3A‐D, no treatment).
F I G U R E  2   Subcellular localization and protein processing is not affected by functional mutations. A, Subcellular localization of ABCA3 
wild‐type (WT) and mutants shown by immunofluorescence and confocal microscopy. A549 cells stably expressing ABCA3 WT or mutants 
were fixed, permeabilized and stained for ABCA3‐HA and lysosomal marker CD63. All proteins are localized in vesicular structures 
resembling lamellar bodies, co‐localizing with CD63. Scale bar represents 10 µm. B, Volume of ABCA3‐HA‐positive vesicles in A549 cells 
stably expressing WT and mutant protein. All analysed mutations led to significantly smaller vesicles compared to WT ABCA3 in A549 cells. 
Results are taken from the functional assay shown in Fig. 3D and are given as means ± SEM of three independent experiments. *P < 0.05 
**P < 0.01 ***P < 0.001 compared to WT. C, Western blot analysis of WT and mutant ABCA3. Molecular masses are indicated on the left, 
β‐actin served as a loading control. D, Quantification of the Western blot shown in (C). Densitometric quantification of protein amount was 
performed with ImageJ. The ratio of 170/190 kDa processing form serves as a marker for correct processing. Mutants do not show different 
ratios from WT, indicating correct trafficking and processing in the cell. Results are means ± SEM of five independent Western blots
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F I G U R E  3   Transport of TopF‐labeled phosphatidylcholine (TopF‐PC) is increased by potentiators ivacaftor and genistein. A549 cells 
expressing wild‐type (WT) or mutant ABCA3 were incubated with liposomes containing TopF‐PC and treated with potentiators for 24 h. 
After fixation and staining for ABCA3‐HA, confocal microscopy pictures were obtained to measure: A, TopF‐PC fluorescence intensity per 
vesicles in all analysed ABCA3‐HA‐positive vesicles relative to WT nt, B, TopF‐PC fluorescence intensity in only TopF‐PC‐filled ABCA3‐
HA‐positive vesicles relative to WT nt, C, Portion of TopF‐PC‐filled vesicles and D, Volume of all analysed ABCA3‐HA‐positive vesicles. 
E, Representative pictures of the experiment. Scale bar represents 10 µm. Pseudo colours were used to stay consistent with former 
experiments. Results are means ± SEM of three independent experiments. *P < 0.05 **P < 0.01 compared to dimethyl sulphoxide (DMSO) 
vehicle controls. nt: no treatment; GEN: genistein, IVA: ivacaftor; TopF‐PC: TopFluor‐labeled phosphatidylcholine
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3.3 | CFTR potentiators ivacaftor and genistein 
improve WT ABCA3 transport function and rescue 
functional defects of some ABCA3 mutants
In WT ABCA3‐HA expressing cells, treatment with 1 µmol/L iva‐
caftor or 10 µmol/L genistein led to a 2.7‐ and twofold increase of 
lipid transport activity, respectively, resulting from an increase in the 
portion of filled vesicles and the fluorescence intensity in filled vesi‐
cles (Figure 3).
In N568D expressing cells, potentiator treatment led to a drastic 
elevation of lipid transport activity from 14% of WT activity to 114% 
in presence of ivacaftor and 90% with genistein, resulting from an 
increase in vesicle volume, portion of filled vesicles and fluorescence 
intensity in filled vesicles to a WT level (Figure 3).
Lipid transport activity of F629L mutant was increased to 47% 
of WT activity by ivacaftor and 46% by genistein treatment, due 
to a significant increase of the portion of filled vesicles (Figure 3A 
and C).
For all other mutant proteins, a slight yet not significant increase 
of lipid transport activity upon potentiator treatment was detected.
Potentiators did not influence the processing of ABCA3 as‐
sessed by Western blotting (Figure S1). To further address speci‐
ficity of their effects, potentiators were also tested in A549 cells 
expressing misfolding mutants Q215K and K1388N. Neither 
their processing and thus nor their function was affected (Figure 
S2), confirming exclusive effects of potentiators on functional 
mutations.
To further rule out a potential influence of the lower protein ex‐
pression of N568D ABCA3‐HA on the results obtained, we addition‐
ally tested another cell clone (N568D‐2) with a higher ABCA3‐HA 
expression than in WT ABCA3‐HA cells and confirmed the results 
reported above (Figure S3).
3.4 | G667R mutant displayed lower affinity 
to genistein and was rescued by increased 
concentrations
Genistein was shown to bind to the LSGGQ signature motif 
in CFTR.39‐41 Since G667R is located in this motif in ABCA3 
(Figure 1B), we suggested a decreased affinity of genistein to the 
mutant protein that might be overcome by higher concentrations 
of the potentiator.
About 50 µmol/L of genistein led to a 2.8‐fold increase of lipid 
transport function in WT‐ABCA3 expressing cells resulting from an 
increase in fluorescence intensity in filled vesicles and the portion of 
filled vesicles, whereas 100  µmol/L genistein did not increase the 
lipid transport (Figure 4A and B).
In G667R expressing cells, 100 µmol/L genistein led to a signif‐
icant increase in lipid transport to 60% of WT function. Assessing 
filled vesicles only, this concentration increased lipid transport to 
a WT level (Figure 4A and B) and also the portion of filled vesi‐
cles and the volume were slightly also not significantly increased 
(Figure 4C and B).
In L1580P ABCA3 expressing cells, no significant effect of 
genistein at increased concentrations was detected.
In our experimental setup, concentrations of 5 µmol/L ivacaftor 
reduced the viability of the cells (data not shown), so no analysis 
of higher concentrations of ivacaftor on lipid transport in G667R 
ABCA3 expressing cells was possible. Viability assays showed the 
toxicity of ivacaftor for the cells (Figure S4).
4  | DISCUSSION
Functional impairment of ABCA3 due to mutations may lead to fatal 
or chronic disturbances of ATII cells and surfactant homoeostasis re‐
sulting in pulmonary diseases like neonatal respiratory distress syn‐
drome and chronic interstitial lung disease. In the present study, we 
showed impaired phospholipid transport function of ABCA3 due to 
distinct disease causing functional mutations that can be rescued by 
the CFTR potentiators ivacaftor and genistein for mutations located 
in the NBD1 of the protein.
The functional defect displayed by mutants N568D and F629L 
was successfully rescued by 1 µmol/L ivacaftor or 10 µmol/L 
genistein. For mutant G667R, 100 µmol/L genistein was sufficient 
to yield a significant increase in lipid transport function. Like de‐
scribed before, mutation N568D led to a functional impairment of 
the ABCA3 protein with only 14% of WT transport function despite 
correct processing and localization.25 Furthermore, the two mutants 
F629L and G667R also showed functional impairment with 12% of 
WT activity but normal processing and localization and were there‐
fore also classified as functional mutations. Ivacaftor and genistein 
treatment elevated transport activity of WT ABCA3 by 2.7‐ and 
twofold, of N568D mutant up to 114% and 90% of WT function, 
respectively, and 46% and 47% for F629L mutant.
Since genistein is presumably binding in the LSGGQ motif of 
NBD1,41 where the mutation G667R is located, the affinity of the 
potentiator to the mutant protein is likely to be lowered like shown 
for G551D in CFTR.39,40 For WT ABCA3, genistein treatment exerted 
potentiating effects up to a concentration of 50 µmol/L and inhibi‐
tory effects at higher concentrations resulting in a bell‐shaped dose‐
response relation like also shown for CFTR.39,42,43 This is explained 
by the assumption of two binding sites for genistein, one high‐affin‐
ity site activating the protein and a second low affinity site exerting 
an inhibitory effect.41,43 In G667R ABCA3 expressing cells, on the 
other hand, only 100 µmol/L genistein yielded a significant increase 
in lipid transport activity to a level of 60% of WT function. Therefore 
the dose‐response curve was shifted to the right compared to WT 
ABCA3, indeed indicating a reduced binding of genistein. Lowered 
affinity of potentiators to CFTR protein harbouring the G551D mu‐
tation was also shown for various other potentiator compounds in‐
cluding ivacaftor.22,44,45 In our cell model, higher concentrations of 
ivacaftor reduced the viability of the cells and we could not evaluate 
their effects on ABCA3 activity. In the TopF‐PC transport assay, a 
concentration of 5 µmol/L ivacaftor impaired cell viability, imped‐
ing evaluation of lipid transport. In such experiments, the cells are 
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incubated at 4°C and in serum‐reduced medium, so that treatment 
with ivacaftor probably adds an additional stressor to the cells. Cell 
type‐specific toxicity may be related to differences in cellular uptake 
of the drug.46
Impaired function of T1114M and L1580P mutants was not 
rescued by potentiator treatment. We recorded a lipid transport 
function of 14% and 10% of WT function for T1114M and L1580P 
as reported before.25,26 For mutation T1114M, Matsumura et al as‐
sessed a rather moderate impairment of 52% of WT ATP hydrolysis 
function but showed a decreased lipid transport function not differ‐
ent from untransfected cells.26
The residue T1114 is located in the TMD, where it likely ensures 
the transmission of conformational changes triggered by NBD di‐
merization to the TMDs and the extracellular domain, required to 
translocate the substrate. Mutation of this threonine to methionine 
likely decouples NBD dimerization and substrate translocation, ex‐
plaining the lack of effect induced by potentiators that stabilize the 
NBD dimer formation to enhance transport function and activity. 
This is further supported by the fact that ivacaftor was also ineffec‐
tive to rescue the L927P CFTR mutant (T1114 is homologous to L935 
in CFTR), which is also located in the eighth transmembrane helix 
and is implicated in conformational changes necessary to open the 
channel.47,48 Furthermore, ivacaftor did not overcome impaired PC 
secretion activity in a TMD mutant of ABCB4.49
Residue L1580 is not directly located in the ATP binding site, 
however its mutation to a proline most likely breaks the helix, in 
which it is located. This will affect the upstream H‐loop, which is 
also implicated in NBD dimerization and ATP binding. In addition to 
F I G U R E  4   G667R ABCA3 mutant 
is rescued by increased concentrations 
of genistein. A549 cells expressing 
wild‐type (WT) or mutant ABCA3 were 
incubated with liposomes containing 
TopFluor‐conjugated PC (TopF‐PC) 
and treated with 50 or 100 μmol/L 
genistein (GEN) for 24 h. After fixation 
and staining for ABCA3‐HA, confocal 
microscopy pictures were obtained 
to measure: A, TopF‐PC fluorescence 
intensity per vesicles in all analysed 
ABCA3‐HA‐positive vesicles relative 
to WT nt, B, TopF‐PC fluorescence 
intensity in only TopF‐PC‐filled ABCA3‐
HA‐positive vesicles relative to WT nt, 
C, Portion of TopF‐PC‐filled vesicles, 
and D, Volume of all analysed ABCA3‐
HA‐positive vesicles. E, Representative 
pictures of the experiment. Scale bar 
represents 10 µm. Pseudo colours were 
used to stay consistent with former 
experiments. Results are means ± SEM 
of three independent experiments. 
*P < 0.05 **P < 0.01 compared to dimethyl 
sulphoxide (DMSO) vehicle controls. nt: 
no treatment; GEN: genistein, TopF‐PC: 
TopFluor‐labeled phosphatidylcholine
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preventing the ATP‐induced NBD dimerization, it is possible that the 
change in conformation might actively prevent the mutated protein 
to reach the active state even in presence of potentiators, explaining 
its non‐responsiveness even at high concentrations.
Furthermore, since ivacaftor was chemically adjusted to specifi‐
cally act on CFTR22 it might only exert effects on regions of ABCA3 
that show very high homology to CFTR, like the NBD1, which might 
explain exclusive effects on mutations located in this domain.
In this study, we used the A549 cell model stably expressing 
WT and mutant ABCA3. A limitation of this approach is the current 
inability to predict the effect of potentiators in patients. On the 
one hand, there is a lack of information on influences of the pa‐
tient‐specific genetic and environmental background. On the other 
hand, the impact of overexpression of ABCA3 is unknown. In future 
studies, those limitations might be overcome by the use of patient‐
specific primary cell cultures or induced pluripotent stem (iPS) cells. 
The optimal model would utilize patient‐derived alveolar epithelial 
type II cells, which are not readily available due to rarity of the pa‐
tients and difficulties to access the terminal area of the lungs.
Nevertheless, the A549 model is a valuable tool to identify 
groups of mutations that can be targeted by the same modulator. 
Similar to cystic fibrosis, where in vitro studies on Fisher rat thyroid 
cells expressing rare CFTR mutants were sufficient for the approval 
of ivacaftor for 23 rare CFTR mutations without need of patient data 
from clinical trials.48,50 Our functional assay using TopF‐PC reliably 
reproduced lipid transport and ATPase activity studies of the mutant 
proteins performed by Matsumura et al25,26 (Table S1) and also rep‐
licated dose‐response relations of genistein in CFTR,39,42,43 making 
it suitable for high‐throughput screens to identify other substances 
that act as potentiators for ABCA3.
Here we showed that some functional ABCA3 mutations were 
rescued by the potentiators genistein and ivacaftor. This provides 
a proof of principle and a first step for the development of pharma‐
cological therapies for interstitial lung diseases caused by ABCA3 
mutations, for which currently no treatment is available.
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